Drug Trial Radar · NCT04875702
Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
650
Planned (sponsor's estimate)
Start
Feb 22, 2024
Primary completion
Sep 1, 2028
Study completion Oct 31, 2028
Sponsor
- Lead sponsor
- Massachusetts General HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- First posted
- May 6, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The TRUST study is a randomized, controlled multicenter study to evaluate the management of gout by comparing two commonly used treatment strategies for gout (TTT vs TTASx) to determine the most beneficial for a patient-centered gout outcomes, as well as relevant cardiovascular-metabolic-renal endpoints.
Conditions
- Gout
Interventions
AllopurinolDrug
For the TTT-SU group: The dose titration algorithm for allopurinol increases every 4 weeks by 100 mg until the target serum urate of 6 mg/dL is reached or a patient requires 800 mg per day of allopurinol. Subjects will require a blood draw for SU every 4 weeks until reaching the target. For the TTASx group: Subjects randomized to the TTASx group will receive anti-inflammatory treatments (naproxen, colchicine, and/or prednisone) for up to six flares over the ensuing three months. Urate lowering therapy (ULT) will only be offered after the third flare during the trial.
Naproxen 250 MGDrug
Naproxen 250 mg p.o. twice daily
Colchicine 0.6 mgDrug
Colchicine 0.6 mg p.o. once daily
Colchicine 1.2 mgDrug
Dose escalation to 0.6 mg p.o. twice daily for patients experiencing breakthrough flares or a dose decrease (0.6 mg p.o. every other day) for patients experiencing gastrointestinal intolerance.
Naproxen 500 MgDrug
dose escalation to 500 mg twice daily for patients experiencing breakthrough flares.
Prednisone 40 mgDrug
For flare glucocorticoids: prednisone taper for 8 days, starting with 40mg (oral) daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency of gout flareTime frame: baseline to two years of follow up
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
The University of Alabama at Birmingham
Birmingham, Alabama · Not yet recruiting
UCLA Health
Santa Monica, California · Not yet recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Brigham and Women's Hospital (BWH)
Boston, Massachusetts · Recruiting
Boston Medical Center (BMC)
Boston, Massachusetts · Not yet recruiting
NYU Langone
New York, New York · Recruiting
West Virginia University (Including Mobile Clinical Trials Unit)
Morgantown, West Virginia · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.